Scientists zero in on how lung cancer spreads

December 24, 2014, Cancer Research UK
Normal cells (left) compared to when the cell ties are broken down (right). Credit: Vaughan et al. Cell Reports.

Cancer Research UK scientists have taken microscopic images revealing that the protein ties tethering cells together are severed in lung cancer cells - meaning they can break loose and spread, according to research published in Cell Reports today.

The researchers at the Cancer Research UK Manchester Institute discovered that the ties which lash together - controlled by a protein called TIAM1 - are chopped up when cell maintenance work goes wrong.

Healthy cells routinely scrap old cell parts so they can be broken down and used again. But this process spirals out of control in lung cancer cells, which scrap too many TIAM1 ties. (This happens because there is too much of a protein, called HUWE1, which is in charge of scrapping TIAM1).

Targeting this recycling process could stop lung cancer from spreading by keeping the cells stuck firmly together.

Lead researcher, Dr Angeliki Malliri, at the Cancer Research UK Manchester Institute at the University of Manchester, said: "This important research shows for the first time how sever ties with their neighbours and start to spread around the body, by hijacking the cells' and sending it into overdrive. Targeting this flaw could help stop lung cancer from spreading."

There are almost 43,500 new cases of in the UK each year. It is the most common cause of cancer deaths and kills more than 35,000 people in the UK each year.

Nell Barrie, Cancer Research UK's senior science information manager, said: "Lung cancer causes more than one in five of all cancer deaths in the UK and it's vital that we find effective new treatments to fight the disease and save more lives.

"Early-stage research like this is essential to find treatments which could one day block cancer spread - which would be a game changer. It's also crucial that we find ways to diagnose the disease earlier, when treatment is more likely to be successful and the is less likely to have spread."

The University of Manchester, including the Cancer Research UK Manchester Institute, joined forces with Cancer Research UK and The Christie NHS Foundation Trust to form the Manchester Cancer Research Centre, allowing doctors and scientists to work closely together to turn scientific advances into patient benefits sooner.

Explore further: Scientists trigger self-destruct switch in lung cancer cells

More information: Vaughan et al. HUWE1 ubiquitylates and degrades the Rac activator TIAM1 promoting cell-cell adhesion disassembly, migration and invasion. Cell Reports. DOI: 10.1016/j.celrep.2014.12.012

Related Stories

Scientists trigger self-destruct switch in lung cancer cells

October 31, 2014
Cancer Research UK scientists have found a drug combination that can trigger the self-destruct process in lung cancer cells - paving the way for new treatments, according to research that will be presented at the National ...

Scientists uncover vast numbers of DNA 'blind spots' that may hide cancer-causing mistakes

November 14, 2014
Cancer Research UK scientists have found more than 400 'blind spots' in DNA which could hide cancer-causing gene faults, according to research published today in Cancer Research.

Scientists pinpoint a new line of defence used by cancer cells

December 8, 2014
Cancer Research UK scientists have discovered a new line of defence used by cancer cells to evade cell death, according to research published in Nature Communications today.

Piggy-backing cells hold clue to skin cancer growth (w/ Video)

July 24, 2014
Skin Cancer cells work together to spread further and faster, according to a new study published in Cell Reports. The discovery could lead to new drugs to tackle melanoma, the most deadly form of skin cancer.

More evidence for impact of lung cancer targeted therapy from practice-changing trial

December 4, 2014
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy.

Immunotherapy could stop resistance to radiotherapy

October 1, 2014
Treating cancers with immunotherapy and radiotherapy at the same time could stop them from becoming resistant to treatment, according to a study published in Cancer Research today.

Recommended for you

Some brain tumors may respond to immunotherapy, new study suggests

December 10, 2018
Immunotherapy has proved effective in treating a number of cancers, but brain tumors have remained stubbornly resistant. Now, a new study suggests that a slow-growing brain tumor arising in patients affected by neurofibromatosis ...

Study finds higher risk of breast cancer for women after giving birth

December 10, 2018
Younger women who have recently had a child may have a higher risk of breast cancer than their peers of the same age who do not have children, according to a large-scale analysis co-led by a University of North Carolina Lineberger ...

A code for reprogramming immune sentinels

December 10, 2018
For the first time, a research team at Lund University in Sweden has successfully reprogrammed mouse and human skin cells into immune cells called dendritic cells. The process is quick and effective, representing a pioneering ...

Researchers develop personalized medicine tool for inherited colorectal cancer syndrome

December 10, 2018
An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes ...

Study shows key enzyme linked to therapy resistance in deadly lung cancer

December 10, 2018
Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth factor receptor (EGFR)-mutant non-small ...

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.